VBL Therapeutics to Present Company Overview at Upcoming Conferences in March
March 03, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate and business...
VBL Therapeutics Announces Launch of the First Israeli Site as Part of the GLOBE International Pivotal Trial for VB-111
February 22, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead...
VBL Therapeutics to Present Corporate Overview at the 18th Annual BIO CEO & Investor Conference
February 01, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 01, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate overview and...
Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033
December 01, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Dec. 1, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the grant of US Patent No. 9,200,056, entitled "A Fas-Chimera Adenovirus Vector" by the United State...
VBL Therapeutics Announces Significant Improvement of 12 Month Overall Survival With VB-111 Compared to Pooled Data From Four Avastin(R) Studies at the Annual Meeting of the Society for Neuro-Oncology
November 19, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 19, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
VBL Therapeutics Data on VB-111 in Combination With Bevacizumab to be Presented at the Annual Meeting of the Society for Neuro-Oncology
November 16, 2015 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...
VBL Therapeutics Announces Third Quarter 2015 Financial Results and Provides Business Update
November 12, 2015 07:00 ET
|
VBL Therapeutics
Initiated GLOBE™ pivotal Phase 3 trial of VB-111 in recurrent glioblastoma (rGBM)
Reported positive, final Phase 2 data of VBL-111 in rGBM at the European Cancer Conference (ECC)...
Vascular Biogenics Ltd. Announces Closing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
November 06, 2015 09:13 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ:VBLT), today announced the closing of its underwritten offering of 2,500,000...
VBL Therapeutics to Report Third Quarter 2015 Financial Results on November 12
November 04, 2015 16:02 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...
Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
November 03, 2015 09:21 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL Therapeutics" or the "Company") (NASDAQ:VBLT), today announced the pricing of an underwritten offering of 2,500,000...